Does the media prefer ALGS or ANIX?

In the previous week, Aligos Therapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.19 beat Aligos Therapeutics' score of 0.64 indicating that Anixa Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALGS or LIXT?

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 403.79%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CUE or ALGS?

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 403.79%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Does the media refer more to CUE or ALGS?

In the previous week, Aligos Therapeutics had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Cue Biopharma. Aligos Therapeutics' average media sentiment score of 0.64 beat Cue Biopharma's score of 0.50 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GUTS or ALGS?

In the previous week, Aligos Therapeutics had 3 more articles in the media than Fractyl Health. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Fractyl Health. Aligos Therapeutics' average media sentiment score of 0.64 beat Fractyl Health's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COYA or ALGS?

In the previous week, Aligos Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Coya Therapeutics. Aligos Therapeutics' average media sentiment score of 0.64 beat Coya Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aligos Therapeutics (ALGS) Competitors

$7.64 +2.05 (+36.71%)

As of 03:57 PM Eastern

Compare

ALGS vs. ANIX, LIXT, CUE, GUTS, and COYA

Should you buy Aligos Therapeutics stock or one of its competitors? MarketBeat compares Aligos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aligos Therapeutics include Anixa Biosciences (ANIX), Lixte Biotechnology (LIXT), Cue Biopharma (CUE), Fractyl Health (GUTS), and Coya Therapeutics (COYA). These companies are all part of the "biotechnology" industry.

How does Aligos Therapeutics compare to Anixa Biosciences?

Aligos Therapeutics (NASDAQ:ALGS) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Anixa Biosciences has lower revenue, but higher earnings than Aligos Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	21.60	-$24.19M	-$7.30	N/A
Anixa Biosciences	$210K	531.36	-$10.93M	-$0.31	N/A

Aligos Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, Aligos Therapeutics had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.19 beat Aligos Therapeutics' score of 0.64 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 403.79%. Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 159.15%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aligos Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Anixa Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Anixa Biosciences' return on equity of -71.12% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Anixa Biosciences	N/A	-71.12%	-62.88%

Summary

Aligos Therapeutics and Anixa Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Lixte Biotechnology?

Aligos Therapeutics (NASDAQ:ALGS) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Lixte Biotechnology has lower revenue, but higher earnings than Aligos Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	21.60	-$24.19M	-$7.30	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Lixte Biotechnology has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Lixte Biotechnology's return on equity of -134.91% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Lixte Biotechnology	N/A	-134.91%	-95.61%

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 403.79%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aligos Therapeutics had 5 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Aligos Therapeutics and 0 mentions for Lixte Biotechnology. Aligos Therapeutics' average media sentiment score of 0.64 beat Lixte Biotechnology's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Lixte Biotechnology	Neutral

Aligos Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Summary

Aligos Therapeutics beats Lixte Biotechnology on 11 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Cue Biopharma has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

In the previous week, Aligos Therapeutics had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Cue Biopharma. Aligos Therapeutics' average media sentiment score of 0.64 beat Cue Biopharma's score of 0.50 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 403.79%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Aligos Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.97	-$26.60M	-$5.58	N/A
Aligos Therapeutics	$2.19M	21.60	-$24.19M	-$7.30	N/A

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cue Biopharma has a net margin of -59.65% compared to Aligos Therapeutics' net margin of -241.01%. Cue Biopharma's return on equity of -98.30% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Summary

Aligos Therapeutics beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Fractyl Health has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

Fractyl Health has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-4,053.15%	-96.41%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Aligos Therapeutics has higher revenue and earnings than Fractyl Health. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,228.66	-$140.95M	-$1.29	N/A
Aligos Therapeutics	$2.19M	21.60	-$24.19M	-$7.30	N/A

Fractyl Health currently has a consensus price target of $5.12, indicating a potential upside of 634.58%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 403.79%. Given Fractyl Health's higher possible upside, analysts plainly believe Fractyl Health is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

60.4% of Aligos Therapeutics shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aligos Therapeutics had 3 more articles in the media than Fractyl Health. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Fractyl Health. Aligos Therapeutics' average media sentiment score of 0.64 beat Fractyl Health's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aligos Therapeutics beats Fractyl Health on 10 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aligos Therapeutics has a net margin of -241.01% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Coya Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

In the previous week, Aligos Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Aligos Therapeutics and 2 mentions for Coya Therapeutics. Aligos Therapeutics' average media sentiment score of 0.64 beat Coya Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has higher revenue and earnings than Aligos Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	13.68	-$21.23M	-$1.15	N/A
Aligos Therapeutics	$2.19M	21.60	-$24.19M	-$7.30	N/A

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 231.17%. Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 403.79%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Aligos Therapeutics beats Coya Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.30M	$3.72B	$7.05B	$12.94B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.05	9.13	269.76	24.76
Price / Sales	21.60	1,273.65	651.81	108.50
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.88	17.66	11.28	6.42
Net Income	-$24.19M	-$13.25M	$3.45B	$347.27M
7 Day Performance	66.13%	5.43%	3.61%	2.52%
1 Month Performance	15.44%	-1.68%	-0.53%	-1.00%
1 Year Performance	-0.62%	61.46%	77.55%	23.29%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	3.7981 of 5 stars	$7.64 +36.7%	$38.50 +403.8%	-27.3%	$47.30M	$2.19M	N/A	90	News Coverage Earnings Report Analyst Forecast Gap Up High Trading Volume
ANIX Anixa Biosciences	4.4463 of 5 stars	$3.41 flat	$8.50 +149.3%	+14.8%	$116.01M	$210K	N/A	5	Positive News Gap Down
LIXT Lixte Biotechnology	0.0939 of 5 stars	$7.51 +4.2%	N/A	+55.5%	$112.80M	N/A	N/A	4	Gap Up
CUE Cue Biopharma	0.2645 of 5 stars	$26.60 -1.0%	N/A	-96.4%	$111.72M	$27.47M	N/A	60
GUTS Fractyl Health	3.2801 of 5 stars	$0.69 +1.2%	$5.12 +647.4%	-27.2%	$108.68M	$90K	N/A	102	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. ANIX, LIXT, CUE, GUTS, and COYA

How does Aligos Therapeutics compare to Anixa Biosciences?

Summary

How does Aligos Therapeutics compare to Lixte Biotechnology?

Summary

How does Aligos Therapeutics compare to Cue Biopharma?

Summary

How does Aligos Therapeutics compare to Fractyl Health?

Summary

How does Aligos Therapeutics compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. ANIX, LIXT, CUE, GUTS, and COYA

How does Aligos Therapeutics compare to Anixa Biosciences?

Which has stronger earnings and valuation, ALGS or ANIX?

Which has more risk and volatility, ALGS or ANIX?

Does the media prefer ALGS or ANIX?

Do insiders and institutionals hold more shares of ALGS or ANIX?

Do analysts prefer ALGS or ANIX?

Is ALGS or ANIX more profitable?

Summary

How does Aligos Therapeutics compare to Lixte Biotechnology?

Which has higher earnings and valuation, ALGS or LIXT?

Is ALGS or LIXT more profitable?

Do insiders & institutionals have more ownership in ALGS or LIXT?

Do analysts prefer ALGS or LIXT?

Does the media favor ALGS or LIXT?

Which has more risk & volatility, ALGS or LIXT?

Summary

How does Aligos Therapeutics compare to Cue Biopharma?

Which has more volatility & risk, CUE or ALGS?

Does the media refer more to CUE or ALGS?

Do analysts prefer CUE or ALGS?

Which has better earnings and valuation, CUE or ALGS?

Do insiders and institutionals believe in CUE or ALGS?

Is CUE or ALGS more profitable?

Summary

How does Aligos Therapeutics compare to Fractyl Health?

Which has more volatility and risk, GUTS or ALGS?

Is GUTS or ALGS more profitable?

Which has preferable earnings & valuation, GUTS or ALGS?

Do analysts rate GUTS or ALGS?

Do insiders & institutionals have more ownership in GUTS or ALGS?

Does the media refer more to GUTS or ALGS?

Summary

How does Aligos Therapeutics compare to Coya Therapeutics?

Do institutionals and insiders have more ownership in COYA or ALGS?

Is COYA or ALGS more profitable?

Which has more risk and volatility, COYA or ALGS?

Does the media favor COYA or ALGS?

Which has stronger earnings and valuation, COYA or ALGS?

Do analysts recommend COYA or ALGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools